Research & Development
Beckman Coulter, MeMed collaborate to expand adoption of host immune response diagnostic test
MeMed developed its BV test to address the management of patients with acute infection in different clinical settings, including emergency departments, and distinguish between bacterial and viral infections early in the diagnostic process.
January 31, 2023
Researchers find hidden bacteria that pose antimicrobial resistance risk to hospital patients
Researchers have found that carriers of specific hidden bacteria have a 14% chance of developing an antibiotic-resistant infection within 30 days of hospitalization.
January 31, 2023
Day Zero awarded $8.2 million in CARB-X funding
Day Zero is developing diagnostic tests that use genome sequencing and machine-learning algorithms to rapidly identify pathogens and their antibacterial-resistance profiles.
October 20, 2022
T2 Biosystems inks distribution agreement in Baltic region
Under the terms of the agreement, the company will sell T2Dx Instruments, along with T2Bacteria, T2Candida, and T2Resistance panels, through an undisclosed distributor.
September 22, 2022
Guidance for antibiotics, diagnostics use in an epidemic
In a statement published Wednesday in Infection Control & Hospital Epidemiology, SHEA provided strategies for hospitals and healthcare personnel to improve antibiotic prescribing when they encounter new infectious disease outbreaks.
September 14, 2022
Method shown to rapidly identify children’s UTIs
The method uses urinalysis results and other variables to predict UTIs and delivers answers before the two to three days needed for culture results.
July 26, 2022
Quest launches long-COVID testing panels for consumers
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for millions of dollars in unnecessary urinalysis testing
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
LumiraDx Q4 revenues drop 65% on lower COVID-19 testing
Patients prefer immediate test results, even when the news is bad
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Vela launches new PCR test for detecting urinary tract infection
The test, called PathoKey MP UTI ID and AMR PCR, is currently for research use only, the company said. It allows for the in vitro detection and categorization of 14 pathogens that cause urinary tract infections and 14 antimicrobial resistance genes that block five antibiotics.
May 18, 2022
Day Zero Diagnostics closes $21M funding round
The company is developing sequencing-based diagnostic technologies that can identify both the species and the antibiotic-resistance profile of a bacterial pathogen within hours.
February 10, 2022
Hologic launches on-demand molecular testing in Europe
Novodiag features real-time polymerase chain reaction and microarray capabilities that allow for multiple pathogens to be identified from a single sample, Hologic said. Its CE-marked IVD test menu includes assays for gastrointestinal infection, antibiotic resistance, and SARS-CoV-2.
October 5, 2021
DNA testing speeds pneumonia diagnoses in COVID-19 patients
Developed at Addenbrooke's Hospital in Cambridge, U.K., with Public Health England, the polymerase chain reaction (PCR) test screens for 52 different pathogens that may cause respiratory illness in intensive care patients.
January 14, 2021
Bruker launches microbe test kit following FDA clearance
Rapid sepsityper identification is crucial for the care of critically ill patients in order to reduce turnaround time for disease-specific treatment, noted Dr. Wolfgang Pusch, executive vice president of microbiology and diagnostics at Bruker. The new test kit can identify microbial species once a blood culture system has detected growth, but it does not test for resistance of antibiotic susceptibility.
January 3, 2021
Firm developing rapid gonorrhea test wins $19M prize
Visby Medical won the prize for its patient-side, disposable, molecular polymerase chain reaction (PCR) diagnostic device that detects Neisseria gonorrhoeae as well as markers of drug resistance. The device is a palm-sized, single-use, disposable device that detects N. gonorrhoeae and can determine whether the bacteria is susceptible to a single-dose antibiotic.
August 5, 2020
Page 1 of 2